Mutation of the Bloom's syndrome (BS) gene, BLM, results in genomic instability. As the first step toward positional cloning of the gene, tight linkage of BLM and FES at 15q26.1 was detected by genotyping affected in families in which the parents are cousins, so-called homozygosity mapping. Linkage disequilibrium between BLM and FES was detected in Ashkenazi Jews with BS, confirming the linkage results and supporting the hypothesis that the increased frequency of the BS mutation in the Ashkenazim is due to founder effect. The mutated BLM gene is inherited identical by descent in BS persons whose parents are cousins or Ashkenazi Jewish; in persons whose parents do not share a common ancestor, BLM can be mutant at different positions within the gene. In such persons, crossing-over within BLM can occur to form a functionally wild-type gene capable of correcting the mutant phenotype of BS cells. In half the cases in which such somatic intragenic recombination had occurred, reduction to homozygosity was detectable distal to BLM but not proximal to it. We localized the cross-over points in corrected cells to a 250 kb genomic segment and isolated therefrom a 4437 bp cDNA that encodes a 1417 amino acid protein homologous to the RecQ subfamily of DExH box-containing DNA and RNA helicases. The identification of BLM as a putative DNA helicase provides a new and powerful tool to investigate the primary defect in BS and the function of the BLM gene product in maintaining the integrity of the genome.
INTRODUCTION
Diverse and complex enzymatic systems exist in the cell that carry out the fundamental processes of the replication and transmission of the genetic material from cell generation to cell generation. To ensure their fidelity, these systems incorporate proofreading capacities of the DNA polymerases and replication machinery, mechanisms that allow DNA replication to bypass damaged DNA (trans-lesion synthesis), repair enzymes that recognize damaged DNA and either repair the damage directly or recruit other enzymes to carry that out, proteins that signal to the cell the presence of DNA damage and that prevent the cell from traversing the cell cycle prior to repair and systems that package and condense the chromatin and that ensure the proper segregation of the chromosomes at mitosis. These systems maintain genomic stability and act to prevent errors that might lead on the one hand to cell death or on the other to abnormal, unregulated cell proliferation.
A time-proven approach for gaining insight into the normal function of biological systems is to investigate rare conditions in which they function abnormally. Genetically determined defects in the systems that maintain genomic stability have been identified in many model organisms, including human. In human genetics, genomic instability first was recognized through cytogenetic observation of chromosomal abnormalities-particularly chromosome breakage-in cultured cells from individuals affected by certain rare syndromes including Bloom's syndrome (BS), Fanconi's anemia, ataxia-telangiectesia, the Nijmegan breakage syndrome, xeroderma pigmentosum and Werner's syndrome. In all of these syndromes, the cytogenetic abnormalities are accompanied by an increase in the rate of either spontaneous somatic mutations, mutagen-induced mutations, or both. This hypermutability provides an explanation for the predisposition to various types of cancers-a common feature in all these syndromes. These clinical entities and several others that lack chromosomal abnormalities (e.g., the Li-Fraumeni syndrome and Lynch syndromes I and II) but that are characterized by genomic instability at the molecular level fall under the category of somatic mutational disorders, of which cancer itself is an important component.
BS is foremost among the genomic instability syndromes in the frequency with which cancers arise in affected individuals, specifically, cancers of the sites and types that affect the general population (Table 1) . It was also the first disorder recognized that exhibits excessive chromosome breakage (1, 2) . In addition to chromosome breakage, present in cultures of proliferating mitogen-stimulated somatic cells are certain configurations, seen also but only rarely in normal cells, that result from interchange of chromatids of homologous chromosomes, termed quadraradials (1); also, an approximately 10-fold increase is demonstrable in the rate of sister-chromatid exchanges (SCEs) in BrdU-treated BS cells compared with normal cells (3) . Thus, added to the somatic mutations that arise by chromosome breakage are those that arise by hyper-recombination: (i) loss-of-heterozygosity due to homologous recombination followed by segregation of mutant alleles distal to the point of crossover (4-6) and (ii) duplications and deletions due to unequal sister-chromatid exchanges between tightly linked repetitive elements or syntenic members of gene families (7) .
*To whom correspondence should be addressed The chromosome abnormalities observed in BS cells pointed to a defect in some fundamental process of DNA metabolism necessary for genomic stability. Retarded replication-fork elongation (8, 9) , abnormal replicational intermediates (10) and the absence of defects in known DNA-repair systems (11) implicated a disturbance of the process of DNA replication itself; however, studies of many of the known enzymatic activities participating in replication failed to disclose the primary defect in BS. Because the identification of the primary defect promised to reveal a previously unknown, central element in DNA replication, a positional cloning strategy was undertaken to isolate the BS gene, BLM. This strategy initiated the molecular genetics of BS leading not only to BLM itself-and, as expected, to biochemical approaches to understanding the primary defect of BS and its pathogenesis-but to a protein intricately involved with the DNA itself-a putative DNA helicase, the absence of which results in hypermutation and hyper-recombination.
LOCALIZATION OF BLM TO 15q26.1
The first step in a positional cloning effort is to identify linkages of mapped polymorphic markers and the defective gene. In human genetics, most families are small, with few affected individuals in them and in autosomal recessive conditions, the predominant family type, which contains a single affected individual in it, provides very little information for detecting genetic linkages. An efficient way to overcome this common limitation is to focus on 'consanguineous' families, that is, families in which the parents of the affecteds are cousins and to use a strategy generally referred to as homozygosity mapping. This method for detecting linkages can be effective provided the frequency of the defective gene in the population(s) from which the families derive is small. The defective gene in nearly all consanguineous families is inherited identical by descent from a single ancestor of the parents of the affected. Just as the defective gene is homozygous in affected individuals from such families, so are polymorphic loci closely flanking the defective gene. In offspring from first-cousin marriages, the median length of homozygous chromatin flanking the gene theoretically is 28 cM (12) . The probability that identity-by-descent occurs by chance at an unlinked locus in a single affected offspring of first cousins is (1/2) 6 . Consequently, the probability that homozygosity will occur by chance at such a locus in n unrelated affected offspring from first-cousin marriages is (1/2) 6n . In principle, then, by conducting a genome scan of affected individuals from just four to six consanguineous families using highly polymorphic microsatellite loci-one roughly every 10-20 cM-one can identify linkages with a high degree of success. In practice, the more families studied, the better the chances of detecting linkage and the smaller the interval in which the defective gene can be localized.
After the BS linkage project in employing the many consanguineous families through the Bloom's Syndrome Registry (13) had been designed, McDaniel and Schultz (14) reported that introduction of a normal human chromosome 15 by microcellmediated chromosome transfer could correct towards normal the high-SCE phenotype of BS cells. Thereafter, our mapping effort was focused on chromosome 15, greatly reducing its scope. The BS homozygosity-mapping study was carried out then in two phases (15) . In the initial phase, 16 individuals with BS from 15 consanguineous families were genotyped employing 25 probes for marker loci on chromosome 15. Additional family members when available were included, although in theory they are not necessary for such an analysis (12) . Fifteen of the 16 affected individuals proved to be homozygous at a polymorphic tetranucleotide repeat situated in intron V of the proto-oncogene FES (15) , which itself had been localized by in situ hybridization to 15q26.1 (16, 17) . With this initial evidence of linkage of BLM and FES, nine BS individuals from six additional families, along with other family members when available, were genotyped at FES, and five additional highly polymorphic DNA markers in a 15 cM region flanking FES (see Fig. 1 ) were genotyped in the entire family set. At FES, where the probability of heterozygosity by chance was 0.66, only one person in the set of 25 individuals genotyped was heterozygous. The pairwise LOD scores at FES calculated using LINKAGE summed to 11.37 at a recombination frequency of 0.001 (15) . Linkage was easily detectable at a locus 5 cM away from BLM; at 10 cM the proportion of homozygotes was still significant (18) , but such proportions had also been detected at unlinked loci (15) . In summary, these data proved that BLM and FES are tightly linked and most probably are within 1 cM of each other on distal chromosome 15q.
BS is believed to be a single-gene disorder as evidenced by the absence of complementation in cell hybrids in which four lymphoblastoid cell lines (LCLs) from BS individuals of three different ethnic backgrounds were fused (1920). In our analysis of consanguineous families, positive LOD scores supporting linkage were found in most, indicating that BLM is mutant in the majority of them. Identity-by-descent of the DNA marker loci flanking FES, however, was absent in four of the families in the study (unpublished observations). The most probable explanation for this observation is that mutation at a locus other than BLM can result in BS. This hypothesis is being investigated presently by cell-hybridization experiments.
FOUNDER EFFECT IN ASHKENAZI JEWS WITH BS

Linkage disequilibrium
BS is commoner in the Ashkenazi Jewish than in any other population known; a survey of BS in Israel in 1977 suggested that more than 1 in 110 Ashkenazi Jews carry blm Ash (21) , which is our term for the mutation at BLM in this population. Several of the polymorphic microsatellite loci found to be tightly linked to BLM by homozygosity mapping were genotyped in affected and unaffected individuals from the Ashkenazi Jewish population. A striking allele association between blm Ash and one of the six alleles at FES, specifically allele C3, and between blm Ash and two related alleles of the CA-repeat locus D15S127 (a locus that is 30 kb proximal to FES), specifically alleles 145 and 147 bp, were detected in Ashkenazi Jews with BS (18) . (The association of two alleles at D15S127 and blm Ash probably results from mutation at D15S127 toggling back and forth between the 145 and 147 bp alleles.)
This linkage disequilibrium confirmed the linkage results and is strong support for a founder-effect hypothesis to explain the increased incidence of BS in the Ashkenazim relative to other populations: a chromosome bearing blm Ash in the genome of a postulated founder individual was carried into Eastern Europe at some time in the fourteenth to seventeenth centuries as the Ashkenazi Jewish population was forming; subsequently, blm Ash and its flanking chromosomal segments increased in frequency in this population as result of genetic drift. In other words, Ashkenazi Jews with BS inherit their mutated BLM gene identical by descent from a common ancestor who lived as many as 30 generations ago, in a sense making the parents of such individuals 29 th cousins.
Linkage-disequilibrium mapping
Four additional highly polymorphic DNA markers that are situated in the 2 Mb region flanking FES and D15S127 which had been developed by us and others (see Fig. 1 ) were used to genotype Ashkenazi Jews with BS and other family members when available, permitting the construction of 46 haplotypes of blm Ash -carrying chromosomes (unpublished observations). Twenty-three of the blm Ash -bearing chromosomes had the same six-locus haplotype which was presumably carried by the founder (scoring the chromosomes carrying the 145 and 147 bp alleles as having founding alleles). The majority of the remaining 23 haplotypes maintained the founding haplotype at FES and D15S127 but had either undergone crossing-over proximal to the two loci, distal to them, or both. Two chromosomes have been identified in which the founding alleles of FES and D15S127 and loci distal to them were absent but in which the founding alleles of the two proximal loci examined were maintained. These results indicated that BLM is situated just proximal to FES and D15S127.
Remarkably, the localization of historical recombinational events in this manner permitted the assignment of BLM to an interval no greater than 250 kb (see Fig. 1 ). However, by the time these linkage relationships were being assigned by linkage-disequilibrium mapping, we had already come upon an important mutational mechanism that takes place in BS somatic cells and fortuitously provided us a new method for pin-pointing BLM exactly. The mechanism we came upon is somatic intragenic recombination; exploitation of such recombination events to map BLM, a method we referred to as somatic crossover-point (SCP) mapping, will be described below.
EVIDENCE FOR ALLELE HETEROGENEITY IN BS
A strikingly elevated SCE rate is uniquely characteristic of BS cells and is present in all cell types examined, including mitogen-stimulated blood T and B lymphocytes in short-term culture; Epstein-Barr virus (EBV)-transformed LCLs in longterm culture; cells from the bone marrow in short-term culture; diploid fibroblast cultures, including fibroblasts from skin, amniotic fluid, chorionic villi and surgical specimens; and aneuploid SV40-transformed fibroblasts cell lines in long-term culture. All persons with BS have high-SCE cells; nonetheless, an exception was recognized in 1977 (22) wherein a small number of blood lymphocytes with a normal SCE rate were found in a minority of persons with clinical BS. This high-SCE/low-SCE mosaicism was investigated by comparing its incidence in subpopulations in persons with BS sorted according to whether or not BLM was known to have been inherited identical by descent (23, 24) . A striking negative correlation emerged: In persons with BS whose parents share a common ancestor, the case in persons born to consanguineous or Ashkenazi Jewish parents (approximately half the BS families), a population of low-SCE cells is almost never found; conversely, the mosaicism occurs almost exclusively in persons with BS whose parents are not known to share a common ancestor. Because those who share a common ancestor predominantly inherit BLM identical by descent, the negative correlation is interpreted to mean that emergence of low-SCE cells in BS depends in some way on the pre-existence of compound heterozygosity, that is, of having two different mutated BLM alleles. A corollary to this is that BS is genetically heterogeneous. We conclude that multiple mutations at BLM are responsible for BS (23) . 
SOMATIC INTRAGENIC RECOMBINATION
The population-cytogenetic data just described indicated that mosaic persons have to be compound heterozygotes. Following this clue, we carried out a genotype analysis of 12 loci syntenic with BLM-six proximal and six distal on chromosome 15-in 11 persons who exhibited high-SCE/low-SCE mosaicism (24) . In five of the 11 persons, polymorphic loci on chromosome 15q distal to BLM that were heterozygous in their high-SCE cells had become homozygous in their low-SCE cells, whereas loci proximal to BLM that were heterozygous on 15q had remained heterozygous. In the remaining six persons, loci both proximal and distal to BLM that were heterozygous in their high-SCE cells had remained heterozygous in their low-SCE cells. These observations are interpreted to mean that intragenic recombination between the paternally derived and the maternally derived mutated sites within BLM is a mechanism that can generate a functionally wild-type BLM gene (Fig. 2) . The newly generated functionally wild-type gene on one chromosome 15 can segregate at mitosis with either the non-recombinant chromatid of the other chromosome 15-allele losses distal to BLM then ensue (reduction to homozygosity)-or it can segregate with the recombinant chromatid that now carries a doubly mutant BLM-allele losses distal to BLM do not ensue. Thus, the low-SCE lymphocytes present in the blood of mosaic persons are the progeny of a somatic stem cell in which intragenic recombination had occurred.
SCP MAPPING
This model, strongly supported by the above genetic evidence, (i) provided an explanation for the low-SCE cells in mosaic persons and (ii) identified a new mechanism by which somatic diversity can be generated in BS. Practically, it provided us with a powerful and efficient method, termed SCP mapping, to determine the exact location of BLM. Because low-SCE LCLs were available in which somatic intragenic recombination in BLM had led to reduction to homozygosity, the precise map position of BLM could be determined in the following way. At loci flanking BLM, we compared the genotypes of these low-SCE LCLs with the constitutional genotypes of the five persons from whom the low-SCE LCLs were derived. The strategy then was to identify (i) the most proximal polymorphic locus that was constitutionally heterozygous and that had been reduced to homozygosity in the low-SCE LCLs and (ii) the most distal polymorphic locus that had remained constitutionally heterozygous in them. BLM would have to be in the short interval defined by the reduced and the unreduced heterozygous markers. The power of this approach would be limited only by the density of polymorphic loci available in the immediate vicinity of BLM.
ISOLATION OF BLM
When BLM was localized to a 2 cM interval flanking FES by homozygosity mapping, in collaboration with J. Groden (University of Cincinnati) we constructed a 2 Mb YAC and P1 contig encompassing FES and identified closely spaced polymorphic DNA markers in the contig (25). With Groden, BLM then was assigned by SCP mapping to a 250 kb interval in this contig, one bounded by the polymorphic loci D15S1108 and by D15S127 (26) (see Fig. 3 ). A 849 bp cDNA clone, 905-28, was isolated by direct cDNA selection using the cosmid clone 905 present in this interval and a 4437 bp cDNA sequence, referred to as H1-5′, was identified by screening cDNA libraries and employing RT-PCR techniques. By Southern analysis, the cDNA hybridizes to single-copy genomic sequences spanning about 100 kb of the genome. The H1-5′ sequence encodes a 1417 amino acid peptide On the upper horizontal line, the order and distances (shown in kilobases) between the polymorphic microsatellite loci were estimated by long-range-restriction mapping (25) . The distance between D15S127 and FES (not indicated) was determined to be 30 kb by restriction enzyme mapping of a cosmid contig (see below). Vertical lines indicate the position of the marker loci and the circle represents the centromere. The interval between loci D15S1108 and D15S127 is expanded below the map. Vertical lines intersecting mark the unmethylated CpG-rich regions identified by long-range restriction mapping and arrows indicate the direction of transcription of three genes in the region. Certain YACs, P1s and cosmids (Y, P and c, respectively) from the contig (25) are depicted by horizontal lines underneath the map. Dashes on the YAC lines indicate internal deletions. At the top of the figure, the horizontal cross-hatched bars indicate regions proximal to BLM that remained heterozygous in the low-SCE LCLs and regions distal to BLM that had become homozygous. The minimal region to which BLM was thus assigned by SCP mapping is represented in black. (B) Autoradiographic evidence showing heterozygosity proximal to BLM and reduction to homozygosity distal to BLM. The four persons of five from whom low-SCE LCLs had been established that were informative at D15S1108 or D15S127 are shown. To determine both the constitutional and the recombinant cell line genotypes, PCRs were carried out using DNA samples prepared from high-SCE cells (P h ) and low-SCE LCLs (P l ) of persons with BS as well as samples from their fathers (PF) and their mothers (PM). These persons are identified by their BS Registry designations. Arrows point to DNA fragments amplified from the heterozygous alleles of the constitutional genotypes, pat (for paternal) and mat (for maternal). Asterisks mark alleles in the low-SCE LCLs that are lost through somatic crossing-over. Lines mark DNA fragments amplified from alleles of the parents but that were not transmitted to the offspring with BS. From one of the four persons with BS, 11 different clonal LCLs were examined; three of the 11 had undergone reduction to homozygosity at loci distal to BLM-as explained elsewhere (24) . Autoradiographic patterns are shown from two of the 11 low-SCE LCLs from 11(IaTh), one representative of cell lines in which allele losses were detected (P l sample on right) and another of cell lines in which they were not (P l sample on left). homologous to the RecQ helicases (Fig. 4) , a subfamily of DExH box-containing DNA and RNA helicases. RNA transcripts 4.5 kb long were identified by northern blot analysis and electrophoretic abnormalities in these RNA transcripts were detected in cells from seven unrelated persons with BS, suggesting that these transcripts are derived from mutant BLM genes. Finally, RT-PCR/SSCP analysis disclosed six unique mutations in nine persons with BS, four that are chain-terminating, two that are putative missense substitutions. One missense mutation affected amino acid residues conserved in all RecQ helicases sequenced to date and the other changed a cysteine in the C-terminal part of BLM to a serine. These data demonstrated that the H1-5′ cDNA sequence encodes BLM and that BS is defined by loss of function of the BLM protein (26) .
PERSPECTIVES FROM THE BLM GENE
The BLM protein is a member of a growing subfamily of proteins, named after its charter member the Escherichia coli gene product RecQ (see Fig. 4 ). These proteins are part of a larger group that contain seven amino acid motifs present in DNA and RNA helicases, implicating BLM as a helicase. RecQ and a human protein isolated from HeLa cells called RECQL exhibit DNA-dependent ATPase and DNA strand-displacement activities that identify them as DNA helicases (27) (28) (29) . Two other members recently added to this subfamily have generated a lot of excitement: the yeast gene product of SGS1, which first was identified by a mutation that suppressed the slow-growth phenotype of mutations in the topoisomerase 3 gene (30) , and the gene product encoded in the Werner's syndrome gene, WRN, that was identified by positional cloning (31) . Both of these gene products are similar to BLM. Besides the 42-44% amino acid identity across the regions of the proteins that contain the seven conserved helicase motifs, these proteins are similar in amino acid length and contain highly negatively charged N-terminal regions (the first 650 residues) and highly positively charged C-terminal regions (the last 350 residues). These similarities in overall structure have raised the possibility that these proteins play similar roles in DNA metabolism.
Thus because Sgs1p is known to interact physically with the products of the yeast topoisomerase genes Top3p (30) and Top2p (32), we would predict that BLM and WRN interact with human topoisomerases. We, joined by N. Neff in the laboratory, are addressing this question using the yeast two-hybrid system and employing biochemical approaches. An antibody to the N-terminal part of BLM has been raised and with western blotting, immunoprecipitation and immunofluorescence now possible, we have initiated investigations in the possible cell-cycle regulation of BLM, in protein complexes purified in vitro that might be active in transcription and in DNA replication, in co-localization of BLM in the cell with other proteins. By defining the systems in which BLM is active, we hope to learn the substrates and intermediates on which BLM operates.
There is material (cell lines and DNAs) available in the laboratory from over 100 BS families (about two-thirds of the families known to us). A study of all the various mutations present in these BS individuals has begun. Already, the spectrum is broad (reference 26 and unpublished observations). Mutations include those that cause premature termination of the protein and those that cause amino acid substitutions. The mutations that cause premature termination include base pair substitutions, small deletions, a small deletion accompanied by an insertion, gross deletions visible by Southern blot analysis, changes that cause abnormal splicing and quite possibly alterations in the BLM promoter.
The BS cell lines in which BLM mutations have been defined provide a powerful system for the analysis of the effects of the BS mutation themselves and for the analysis of the functions and activities of the wild-type gene. By transfecting the wild-type BLM cDNA into BS cells that contain a 'knock-out' mutation, we have recently achieved correction of the high-SCE phenotype of those cells. This system permits the analysis of BLM genes in which mutations have been introduced in vitro, and it is the first step toward gene therapy in BS.
With the gene and BS mutations in hand, definitive proof of the somatic intragenic recombination model of low-SCE cells in BS can be formulated. Low-SCE cells in which reduction to homozygosity occurred should contain the proximal BS mutation only, whereas cells in which reduction to homozygosity did not occur should contain a doubly mutant BLM, the reciprocal product of the crossing-over event that generated the wild-type gene. However at least two cases of high-SCE/low-SCE mosaicism in fact occurred in persons who are homozygotes; there must be other mutational mechanisms that generate a functionally wild-type gene, an area of continuing interest to this laboratory.
At present, SCP mapping has only been carried out in BS, possibly because the rate of somatic intragenic recombination is so much higher in BS than in normal and other types of mutant cells. It might be possible to generate hyper-recombination in normal and other cells by producing dominant negative BS mutations, for example, with anti-sense BLM RNA or overexpression of mutant BLM gene products. Producing hyper-recombination in cells from other rare autosomal recessive disorders in which the primary defect is unknown might increase the rate of recombination in heteroallelic mutant genes and permit the application of selective techniques to isolate corrected cells in which intragenic recombination has occurred. Corrected cells generated this way then would permit the rapid chromosomal localization of these genes. Thus, making dominant negative BLM mutations would be a first step toward making SCP mapping a more generally applicable gene-mapping tool.
CONCLUSIONS
With the tentative identification of BLM as a DNA helicase intricately involved in DNA metabolism, the isolation of the BS gene provides a valuable experimental tool for the investigation of nuclear processes in which BLM participates. There are many helicases, but in human cells the BLM helicase is important: the major consequence for the cell of absence of the normal function of the BLM gene product is an unacceptably high rate of mutation, including hyper-recombination. The cloning of BLM opens the way to a deeper understanding of the genomic instability in BS cells and, more importantly, of the normal cellular systems that maintain the integrity of the genome in somatic cells.
